Agenus Inc

AGEN

Equity

ISIN null / Valor 134326284

NASDAQ (2025-11-18)

USD 4.23-2.08%

Agenus Inc
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Agenus Inc is a biotechnology firm focused on the discovery, manufacturing, and development of immuno-oncology (I-O) therapeutics. The company aims to enhance the efficacy of cancer treatments by employing a comprehensive approach that includes a variety of therapeutic modalities. These include a broad array of antibody therapeutics, adoptive cell therapies—which are advanced through its subsidiary MiNK Therapeutics—as well as adjuvants and vaccines, developed with the expertise of another subsidiary, SaponiQx. Agenus's strategy revolves around leveraging these diverse platforms to develop combination therapies that can potentially benefit a wider patient population by targeting various aspects of the immune system to fight cancer more effectively.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue and Net Loss

Agenus reported revenue of $25.7 million for Q2 2025 and $49.8 million for Q2 year-to-date 2025, primarily from non-cash royalty revenue, compared to $51.5 million in Q2 year-to-date 2024. The net loss for Q2 year-to-date 2025 was $56.4 million, or $2.03 per share, significantly improved from $118.3 million, or $5.56 per share, in the same period last year.

Reduced Cash Burn

Cash used in operations decreased to $45.8 million for Q2 year-to-date 2025 from $76.4 million for Q2 year-to-date 2024. This reduction is a result of prudent cost management and is expected to continue into the second half of 2025. Agenus is actively negotiating collaborations that could provide additional cash resources.

Liquidity and Future Outlook

With the anticipated $91 million capital infusion from the Zydus Lifesciences collaboration expected to close in Q3 2025, combined with the current cash balance of $9.5 million and post-Q2 capital raised of $5.2 million, Agenus expects to fund the launch of its Phase 3 trial. The company is also in negotiations to secure additional funding streams from ongoing partnerships and the commercial prospects of BOT/BAL in regions beyond North America, Europe, and Japan.

Summarized from source with an LLMView Source

Key figures

60.8%1Y

-93.0%3Y

-94.3%5Y

Performance

103%1Y

111%3Y

98.2%5Y

Volatility